Klik om onze verklaring over toegankelijkheid

Populaire zoekopdrachten

Man with short brown hair, beard, and glasses wearing a light blue blazer and white shirt, smiling at the camera against a plain gray background—perfect for profiles of Chicago lawyers or intellectual property law professionals.

Jason N. Mock

Partner

Terug

Jason N. Mock

Partner

Washington, D.C. 202.295.4775

Praktijk

Onderwijs

  • The George Washington University Law School (J.D., with honors)
    • Member, Federal Circuit Bar Journal
    • George S. Hastings IP Scholar
    • Finnegan Prize for Intellectual Property Law
  • University of Georgia (Ph.D., summa cum laude)
    • Pharmaceutical and biomedical science
  • University of Georgia (B.S., magna cum laude)
    • Biotechnology, and agricultural and applied economics

Toelatingen

  • District Columbia
  • Virginia
  • Amerikaans octrooi- en merkenbureau

Dr. Jason Mock is an intellectual property attorney that helps organizations of all sizes in every facet of the patent life cycle. Whether a client is developing and obtaining new patent rights, managing a complex portfolio, performing due diligence for a transaction, or enforcing or defending its rights, Jason has the experience to guide his clients and serve as a trusted advisor.

Jason’s practice spans industries including pharmaceuticals, diagnostics, biotechnology, synthetic biology and biomanufacturing, food science, and agriculture. He has a depth of knowledge to help his clients keep pace in changing environments and realize value from their IP. Jason’s clients range from startups and universities to multinational corporations. He is a member of the firm’s Chemical, Biotechnology, & Pharmaceutical Practice and the PTAB Trials Practice.

Presentaties en publicaties

  • J. Mock, T. Yan, and K. Sharon, “IPR proactive defense measures – strategies and considerations for patent owners,” PTAB Trial Insights (May 2016)
  • J. Mock, “Split Federal Circuit Upholds Constitutionality of Single PTAB Panels Rendering Both Institution & Final Written Decisions,” PTAB Trial Insights (January 2016)
  • Author, “Post-Grant Proceedings at the USPTO and the Rising Tide of Federal Circuit Appeals,” The Federal Circuit Bar Journal (September 2015)
  • Co-author, “The Road Ahead for Kyle Bass’s IPRs,” Law360 (August 2015)
  • Co-author, “Will New PTAB Rules Impact IPRs Filed by Kyle Bass Hedge Fund?” The National Law Review (August 2015)
  • Co-author, “Survey of State Laws Against Bad-Faith Patent Assertion,” Bloomberg BNA Patent, Trademark & Copyright Journal (August 2014)
  • Co-author, “Role of the Phospholipase A2 Receptor in Liposome Drug Delivery in Prostate Cancer Cells,” Mol. Pharmaceuticals (2014)
  • Co-author, “Evidence for Distinct Mechanisms of Uptake and Antitumor Activity of Secretory Phospholipase A2 Responsive Liposomes in Prostate Cancer,” Integr. Biol. (2012)
  • Co-author, “Haloenol Pyranones and Morpholinones as Antineoplastic Agents of Prostate Cancer,” Bioorg. and Med. Chem. Letters (2012)
  • Co-author, “Secretory Phospholipase A2 Responsive Liposomes,” J. Pharm. Sci. (2011)
  • Co-author, Enhanced Antitumor Activity of Low-Dose Continuous Administration Schedules of Topotecan in Prostate Cancer,” Cancer Bio. and Therapy (2011)
1 februari 2024 Persberichten

Foley kondigt 23 nieuwe partners aan

Foley & Lardner LLP heeft 23 advocaten gekozen tot partner van het kantoor, met ingang van 1 februari 2024.
Assorted pills and capsules of various colors and shapes scattered on a blue background, with empty space on the left side, symbolizing complex cases that lawyers in Chicago or a corporate law office might handle.
29 maart 2023 Gezondheidszorgwet vandaag

De klif van het BioFarma-octrooi: 2023 en daarna

Een "patent cliff" verwijst naar het einde van de IP-bescherming voor een geneesmiddel dat marktexclusiviteit genoot sinds de lancering. Verschillende vormen van wettelijke exclusiviteit kunnen de bescherming voor medicijnen af en toe verlengen, maar over het algemeen beginnen we generieke concurrenten op de markt te zien wanneer een medicijn zijn patentbescherming verliest.
Close-up van talloze doorschijnende blauwe bollen tegen een lichte achtergrond met het logo van Foley & Lardner LLP in de rechterbovenhoek. Dit weerspiegelt de innovatieve geest van dit toonaangevende advocatenkantoor.
27 februari 2023 Gezondheidszorgwetgeving vandaag

Sectortrends gezondheidszorg en biowetenschappen voor 2023

Foley is er klaar voor om bedrijven in de gezondheidszorg en biowetenschappen strategisch te adviseren bij elke stap van hun reis en in alle fasen van hun levenscyclus.
August 19, 2020 Blogs

PTAB’s Motion to Amend Pilot Program: Review of Initial Results

We analyze the initial results of the pilot program for motions to amend ("MTA") and conclude that, while it is still early in development and subsequent results could lead to new insights, for now at least patent owners may be better off using alternative approaches such as reissue or ex parte reexamination.
March 31, 2020 Foley Viewpoints

COVID-19: Patent Procurement and Licensing

Public health officials have said that we can expect the coronavirus pandemic to last for months—and the underlying virus will likely be with us for the long term. Meanwhile, the response to the COVID-19 pandemic has included a flurry of innovation.
Empty courtroom with wooden desks and chairs, judge's bench at the front, American flag, and ornate wood paneling—a setting familiar to Chicago lawyers specializing in intellectual property law.
October 15, 2019 Blogs

While Tempting, PTAB Requests for Rehearing Face Long Odds

When the PTAB renders a decision, one of the parties is almost certain to be unhappy. Providing appropriate advice in the face of an undesired outcome requires an understanding of the odds of changing the outcome.
Bekijk alle inzichten
Bekijk Newsroom